doi: 10.1038/clpt.2010.1.
Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?
Affiliations
- PMID: 20305672
- DOI: 10.1038/clpt.2010.1
Item in Clipboard
Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?
Clin Pharmacol Ther.
2010 Apr.
Abstract
Interleukin-6 (IL-6) has been linked to a myriad of diseases associated with inflammation, including rheumatoid arthritis (RA), Crohn's disease, and several types of cancer. In 2009 the US Food and Drug Administration accepted a complete-response submission for the use of Actemra (tocilizumab), the first humanized IL-6 receptor-inhibiting monoclonal antibody, for the treatment of RA. Although this treatment will certainly help in managing inflammatory disorders such as RA, we suggest that side effects of such blockade may be excess weight gain and hyperlipidemia.
Similar articles
-
Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.Drugs Today (Barc). 2006 Sep;42(9):559-76. doi: 10.1358/dot.2006.42.9.1025692. Drugs Today (Barc). 2006. PMID: 17028666 Review.
-
Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.Drug Des Devel Ther. 2010 Oct 1;4:263-78. doi: 10.2147/DDDT.S14099. Drug Des Devel Ther. 2010. PMID: 21116333 Free PMC article. Review.
-
Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?Expert Opin Investig Drugs. 2009 Nov;18(11):1687-99. doi: 10.1517/14728220903185939. Expert Opin Investig Drugs. 2009. PMID: 19715449 Review.
-
Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date.Drug Des Devel Ther. 2016 Sep 26;10:3083-3098. doi: 10.2147/DDDT.S99898. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27713619 Free PMC article. Review.
-
The clinical efficacy of tocilizumab in rheumatoid arthritis.Drugs Today (Barc). 2009 Mar;45(3):189-97. doi: 10.1358/dot.2009.45.3.1343794. Drugs Today (Barc). 2009. PMID: 19436841 Review.
Cited by
-
IL-6 biology: implications for clinical targeting in rheumatic disease.Nat Rev Rheumatol. 2014 Dec;10(12):720-7. doi: 10.1038/nrrheum.2014.127. Epub 2014 Aug 19. Nat Rev Rheumatol. 2014. PMID: 25136784 Review.
-
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH.iScience. 2022 Dec 30;26(1):105905. doi: 10.1016/j.isci.2022.105905. eCollection 2023 Jan 20. iScience. 2022. PMID: 36691622 Free PMC article. Review.
-
Biomarker as a research tool in linking exposure to air particles and respiratory health.Biomed Res Int. 2015;2015:962853. doi: 10.1155/2015/962853. Epub 2015 Apr 23. Biomed Res Int. 2015. PMID: 25984536 Free PMC article. Review.
-
Adipose tissue inflammation in glucose metabolism.Rev Endocr Metab Disord. 2014 Mar;15(1):31-44. doi: 10.1007/s11154-013-9274-4. Rev Endocr Metab Disord. 2014. PMID: 24048715 Review.
-
Induction of immune tolerance in the treatment of rheumatoid arthritis.Nat Rev Rheumatol. 2011 May;7(5):272-81. doi: 10.1038/nrrheum.2011.36. Epub 2011 Apr 5. Nat Rev Rheumatol. 2011. PMID: 21468144 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
